REST THERAPEUTICS

ReST Therapeutics Receives FDA Clearance for First-in-Human Trial of Novel Early PTSD Intervention RST-101

- ReST Therapeutics announced FDA acceptance of its IND application for RST-101, enabling the first-in-human clinical trial for early PTSD intervention. - RST-101 is a small molecule NMDA antagonist designed to target trauma memory consolidation during the critical early window following traumatic exposure. - The therapeutic represents a paradigm shift from current PTSD treatments by preventing chronic disorder development rather than managing established symptoms. - PTSD affects approximately 300 million people globally with about 2 million new cases annually, representing a significant unmet medical need.